Finasteride, when taken orally, is a medication used to treat symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It is also prescribed to treat male pattern hair loss (androgenetic alopecia) in men. Finasteride works by inhibiting the action of the enzyme 5-alpha reductase, which converts the male hormone testosterone to dihydrotestosterone (DHT). By reducing DHT levels in the body, finasteride helps to shrink the prostate and promote hair regrowth in men with male pattern baldness. It is important to note that finasteride should only be taken as prescribed by a healthcare provider, as it can have side effects and may not be suitable for everyone.
The global Finasteride (Oral Route) market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The 鈥淔inasteride (Oral Route) Industry Forecast鈥� looks at past sales and reviews total world Finasteride (Oral Route) sales in 2023, providing a comprehensive analysis by region and market sector of projected Finasteride (Oral Route) sales for 2024 through 2030. With Finasteride (Oral Route) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Finasteride (Oral Route) industry.
This Insight Report provides a comprehensive analysis of the global Finasteride (Oral Route) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Finasteride (Oral Route) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Finasteride (Oral Route) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Finasteride (Oral Route) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Finasteride (Oral Route).
United States market for Finasteride (Oral Route) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Finasteride (Oral Route) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Finasteride (Oral Route) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Finasteride (Oral Route) players cover Merck, Sandoz, Actavis, Cipla and RelonChem, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Finasteride (Oral Route) market by product type, application, key manufacturers and key regions and countries.
Segmentation by type
1mg
5mg
Segmentation by application
Urology
Dermatology
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Sandoz
Actavis
Cipla
RelonChem
Dr. Reddy
Accord Pharmaceuticals
Hangzhou Kangenbei Pharmaceutical Co., Ltd
Hunan Zhengqing Pharmaceutical Group Co., Ltd
Tianfang Pharmaceutical Co., Ltd
Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd
Shanghai Hyundai Pharmaceutical Co., Ltd
Hunan Baicao Pharmaceutical Co., Ltd
Guangdong Yishu Pharmaceutical Co., Ltd
CR SECCO Pharmaceutical Co., Ltd
Shanghai Xinya Pharmaceutical Minhang Co., Ltd
Renhetang Pharmaceutical Company Limited
Runenberg Pharmaceuticals Ltd
Nanjing Shenghe Pharmaceutical Co., Ltd
Nanjing Sea Whale Pharmaceutical Co., Ltd
Key Questions Addressed in this Report
What is the 10-year outlook for the global Finasteride (Oral Route) market?
What factors are driving Finasteride (Oral Route) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Finasteride (Oral Route) market opportunities vary by end market size?
How does Finasteride (Oral Route) break out type, application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Finasteride (Oral Route) Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Finasteride (Oral Route) by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Finasteride (Oral Route) by Country/Region, 2019, 2023 & 2030
2.2 Finasteride (Oral Route) Segment by Type
2.2.1 1mg
2.2.2 5mg
2.3 Finasteride (Oral Route) Sales by Type
2.3.1 Global Finasteride (Oral Route) Sales Market Share by Type (2019-2024)
2.3.2 Global Finasteride (Oral Route) Revenue and Market Share by Type (2019-2024)
2.3.3 Global Finasteride (Oral Route) Sale Price by Type (2019-2024)
2.4 Finasteride (Oral Route) Segment by Application
2.4.1 Urology
2.4.2 Dermatology
2.5 Finasteride (Oral Route) Sales by Application
2.5.1 Global Finasteride (Oral Route) Sale Market Share by Application (2019-2024)
2.5.2 Global Finasteride (Oral Route) Revenue and Market Share by Application (2019-2024)
2.5.3 Global Finasteride (Oral Route) Sale Price by Application (2019-2024)
3 Global Finasteride (Oral Route) by Company
3.1 Global Finasteride (Oral Route) Breakdown Data by Company
3.1.1 Global Finasteride (Oral Route) Annual Sales by Company (2019-2024)
3.1.2 Global Finasteride (Oral Route) Sales Market Share by Company (2019-2024)
3.2 Global Finasteride (Oral Route) Annual Revenue by Company (2019-2024)
3.2.1 Global Finasteride (Oral Route) Revenue by Company (2019-2024)
3.2.2 Global Finasteride (Oral Route) Revenue Market Share by Company (2019-2024)
3.3 Global Finasteride (Oral Route) Sale Price by Company
3.4 Key Manufacturers Finasteride (Oral Route) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Finasteride (Oral Route) Product Location Distribution
3.4.2 Players Finasteride (Oral Route) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Finasteride (Oral Route) by Geographic Region
4.1 World Historic Finasteride (Oral Route) Market Size by Geographic Region (2019-2024)
4.1.1 Global Finasteride (Oral Route) Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Finasteride (Oral Route) Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Finasteride (Oral Route) Market Size by Country/Region (2019-2024)
4.2.1 Global Finasteride (Oral Route) Annual Sales by Country/Region (2019-2024)
4.2.2 Global Finasteride (Oral Route) Annual Revenue by Country/Region (2019-2024)
4.3 Americas Finasteride (Oral Route) Sales Growth
4.4 APAC Finasteride (Oral Route) Sales Growth
4.5 Europe Finasteride (Oral Route) Sales Growth
4.6 Middle East & Africa Finasteride (Oral Route) Sales Growth
5 Americas
5.1 Americas Finasteride (Oral Route) Sales by Country
5.1.1 Americas Finasteride (Oral Route) Sales by Country (2019-2024)
5.1.2 Americas Finasteride (Oral Route) Revenue by Country (2019-2024)
5.2 Americas Finasteride (Oral Route) Sales by Type
5.3 Americas Finasteride (Oral Route) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Finasteride (Oral Route) Sales by Region
6.1.1 APAC Finasteride (Oral Route) Sales by Region (2019-2024)
6.1.2 APAC Finasteride (Oral Route) Revenue by Region (2019-2024)
6.2 APAC Finasteride (Oral Route) Sales by Type
6.3 APAC Finasteride (Oral Route) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Finasteride (Oral Route) by Country
7.1.1 Europe Finasteride (Oral Route) Sales by Country (2019-2024)
7.1.2 Europe Finasteride (Oral Route) Revenue by Country (2019-2024)
7.2 Europe Finasteride (Oral Route) Sales by Type
7.3 Europe Finasteride (Oral Route) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Finasteride (Oral Route) by Country
8.1.1 Middle East & Africa Finasteride (Oral Route) Sales by Country (2019-2024)
8.1.2 Middle East & Africa Finasteride (Oral Route) Revenue by Country (2019-2024)
8.2 Middle East & Africa Finasteride (Oral Route) Sales by Type
8.3 Middle East & Africa Finasteride (Oral Route) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Finasteride (Oral Route)
10.3 Manufacturing Process Analysis of Finasteride (Oral Route)
10.4 Industry Chain Structure of Finasteride (Oral Route)
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Finasteride (Oral Route) Distributors
11.3 Finasteride (Oral Route) Customer
12 World Forecast Review for Finasteride (Oral Route) by Geographic Region
12.1 Global Finasteride (Oral Route) Market Size Forecast by Region
12.1.1 Global Finasteride (Oral Route) Forecast by Region (2025-2030)
12.1.2 Global Finasteride (Oral Route) Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Finasteride (Oral Route) Forecast by Type
12.7 Global Finasteride (Oral Route) Forecast by Application
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Finasteride (Oral Route) Product Portfolios and Specifications
13.1.3 Merck Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Sandoz
13.2.1 Sandoz Company Information
13.2.2 Sandoz Finasteride (Oral Route) Product Portfolios and Specifications
13.2.3 Sandoz Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Sandoz Main Business Overview
13.2.5 Sandoz Latest Developments
13.3 Actavis
13.3.1 Actavis Company Information
13.3.2 Actavis Finasteride (Oral Route) Product Portfolios and Specifications
13.3.3 Actavis Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Actavis Main Business Overview
13.3.5 Actavis Latest Developments
13.4 Cipla
13.4.1 Cipla Company Information
13.4.2 Cipla Finasteride (Oral Route) Product Portfolios and Specifications
13.4.3 Cipla Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Cipla Main Business Overview
13.4.5 Cipla Latest Developments
13.5 RelonChem
13.5.1 RelonChem Company Information
13.5.2 RelonChem Finasteride (Oral Route) Product Portfolios and Specifications
13.5.3 RelonChem Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 RelonChem Main Business Overview
13.5.5 RelonChem Latest Developments
13.6 Dr. Reddy
13.6.1 Dr. Reddy Company Information
13.6.2 Dr. Reddy Finasteride (Oral Route) Product Portfolios and Specifications
13.6.3 Dr. Reddy Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Dr. Reddy Main Business Overview
13.6.5 Dr. Reddy Latest Developments
13.7 Accord Pharmaceuticals
13.7.1 Accord Pharmaceuticals Company Information
13.7.2 Accord Pharmaceuticals Finasteride (Oral Route) Product Portfolios and Specifications
13.7.3 Accord Pharmaceuticals Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Accord Pharmaceuticals Main Business Overview
13.7.5 Accord Pharmaceuticals Latest Developments
13.8 Hangzhou Kangenbei Pharmaceutical Co., Ltd
13.8.1 Hangzhou Kangenbei Pharmaceutical Co., Ltd Company Information
13.8.2 Hangzhou Kangenbei Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.8.3 Hangzhou Kangenbei Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Hangzhou Kangenbei Pharmaceutical Co., Ltd Main Business Overview
13.8.5 Hangzhou Kangenbei Pharmaceutical Co., Ltd Latest Developments
13.9 Hunan Zhengqing Pharmaceutical Group Co., Ltd
13.9.1 Hunan Zhengqing Pharmaceutical Group Co., Ltd Company Information
13.9.2 Hunan Zhengqing Pharmaceutical Group Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.9.3 Hunan Zhengqing Pharmaceutical Group Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Hunan Zhengqing Pharmaceutical Group Co., Ltd Main Business Overview
13.9.5 Hunan Zhengqing Pharmaceutical Group Co., Ltd Latest Developments
13.10 Tianfang Pharmaceutical Co., Ltd
13.10.1 Tianfang Pharmaceutical Co., Ltd Company Information
13.10.2 Tianfang Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.10.3 Tianfang Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Tianfang Pharmaceutical Co., Ltd Main Business Overview
13.10.5 Tianfang Pharmaceutical Co., Ltd Latest Developments
13.11 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd
13.11.1 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Company Information
13.11.2 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.11.3 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Main Business Overview
13.11.5 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Latest Developments
13.12 Zhejiang Xianju Pharmaceutical Co., Ltd
13.12.1 Zhejiang Xianju Pharmaceutical Co., Ltd Company Information
13.12.2 Zhejiang Xianju Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.12.3 Zhejiang Xianju Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Zhejiang Xianju Pharmaceutical Co., Ltd Main Business Overview
13.12.5 Zhejiang Xianju Pharmaceutical Co., Ltd Latest Developments
13.13 Shanghai Hyundai Pharmaceutical Co., Ltd
13.13.1 Shanghai Hyundai Pharmaceutical Co., Ltd Company Information
13.13.2 Shanghai Hyundai Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.13.3 Shanghai Hyundai Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Shanghai Hyundai Pharmaceutical Co., Ltd Main Business Overview
13.13.5 Shanghai Hyundai Pharmaceutical Co., Ltd Latest Developments
13.14 Hunan Baicao Pharmaceutical Co., Ltd
13.14.1 Hunan Baicao Pharmaceutical Co., Ltd Company Information
13.14.2 Hunan Baicao Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.14.3 Hunan Baicao Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Hunan Baicao Pharmaceutical Co., Ltd Main Business Overview
13.14.5 Hunan Baicao Pharmaceutical Co., Ltd Latest Developments
13.15 Guangdong Yishu Pharmaceutical Co., Ltd
13.15.1 Guangdong Yishu Pharmaceutical Co., Ltd Company Information
13.15.2 Guangdong Yishu Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.15.3 Guangdong Yishu Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Guangdong Yishu Pharmaceutical Co., Ltd Main Business Overview
13.15.5 Guangdong Yishu Pharmaceutical Co., Ltd Latest Developments
13.16 CR SECCO Pharmaceutical Co., Ltd
13.16.1 CR SECCO Pharmaceutical Co., Ltd Company Information
13.16.2 CR SECCO Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.16.3 CR SECCO Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 CR SECCO Pharmaceutical Co., Ltd Main Business Overview
13.16.5 CR SECCO Pharmaceutical Co., Ltd Latest Developments
13.17 Shanghai Xinya Pharmaceutical Minhang Co., Ltd
13.17.1 Shanghai Xinya Pharmaceutical Minhang Co., Ltd Company Information
13.17.2 Shanghai Xinya Pharmaceutical Minhang Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.17.3 Shanghai Xinya Pharmaceutical Minhang Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Shanghai Xinya Pharmaceutical Minhang Co., Ltd Main Business Overview
13.17.5 Shanghai Xinya Pharmaceutical Minhang Co., Ltd Latest Developments
13.18 Renhetang Pharmaceutical Company Limited
13.18.1 Renhetang Pharmaceutical Company Limited Company Information
13.18.2 Renhetang Pharmaceutical Company Limited Finasteride (Oral Route) Product Portfolios and Specifications
13.18.3 Renhetang Pharmaceutical Company Limited Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.18.4 Renhetang Pharmaceutical Company Limited Main Business Overview
13.18.5 Renhetang Pharmaceutical Company Limited Latest Developments
13.19 Runenberg Pharmaceuticals Ltd
13.19.1 Runenberg Pharmaceuticals Ltd Company Information
13.19.2 Runenberg Pharmaceuticals Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.19.3 Runenberg Pharmaceuticals Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.19.4 Runenberg Pharmaceuticals Ltd Main Business Overview
13.19.5 Runenberg Pharmaceuticals Ltd Latest Developments
13.20 Nanjing Shenghe Pharmaceutical Co., Ltd
13.20.1 Nanjing Shenghe Pharmaceutical Co., Ltd Company Information
13.20.2 Nanjing Shenghe Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.20.3 Nanjing Shenghe Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.20.4 Nanjing Shenghe Pharmaceutical Co., Ltd Main Business Overview
13.20.5 Nanjing Shenghe Pharmaceutical Co., Ltd Latest Developments
13.21 Nanjing Sea Whale Pharmaceutical Co., Ltd
13.21.1 Nanjing Sea Whale Pharmaceutical Co., Ltd Company Information
13.21.2 Nanjing Sea Whale Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolios and Specifications
13.21.3 Nanjing Sea Whale Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue, Price and Gross Margin (2019-2024)
13.21.4 Nanjing Sea Whale Pharmaceutical Co., Ltd Main Business Overview
13.21.5 Nanjing Sea Whale Pharmaceutical Co., Ltd Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
